Back to results
US 10,946,094 B2Granted
Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer
AssigneeCornell University
InventorsRonald G. Crystal, Arash Rafii Tabrizi
Life of this patent
Estimating the term…
Abstract
The invention provides a method of treating ovarian cancer in a patient by administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.
Claims2
A method of treating ovarian cancer in a patient, the method comprising administering to the patient:
- (a) paclitaxel and
- (b) a AAVrh10 vector comprising a promoter operably linked to a gene encoding bevacizumab,
- wherein the paclitaxel is administered to the patient prior to the administration of the AAVrh10 vector, and
- wherein the AAVrh10 vector is administered by intraperitoneal injection to the patient not more than once over a 30 day time period,
- thereby treating the ovarian cancer in the patient.
2 more elements
A method of treating ovarian cancer in a patient, the method comprising administering to the patient:
- (a) topetcan and
- (b) a AAVrh10 vector comprising a promoter operably linked to a gene encoding bevacizumab,
- wherein the topetcan is administered to the patient prior to the administration of the AAVrh10 vector, and
- wherein the AAVrh10 vector is administered by intraperitoneal injection to the patient not more than once over a 30 day time period,
- thereby treating the ovarian cancer in the patient.
2 more elements
Dependencies are inferred from the claim text.